Asenapine in the treatment of older adults with bipolar disorder

Sajatovic, Martha; Dines, Philipp; Fuentes-Casiano, Edna; Athey, Melanie; Cassidy, Kristin A.; Sams, Johnny; Clegg, Kathleen A.; Locala, Joseph A.; Stagno, Susan J.; Tatsuoka, Curtis

doi:10.1002/gps.4213

Cited by 32 publications

(22 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quetiapine (level 2)655 can be considered as second‐line. Asenapine (level 4),656, 657 aripiprazole (level 4),658 risperidone (level 4),659 or carbamazepine (level 4)654 may be applied as third‐line treatments. For treatment‐resistant episodes, clozapine (level 4)660 and ECT (level 4)654 should also be considered.…”

Section: Specific Populationsmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

The Canadian Network for Mood and Anxiety Treatments (CANMAT) previously published treatment guidelines for bipolar disorder in 2005, along with international commentaries and subsequent updates in 2007, 2009, and 2013. The last two updates were published in collaboration with the International Society for Bipolar Disorders (ISBD). These 2018 CANMAT and ISBD Bipolar Treatment Guidelines represent the significant advances in the field since the last full edition was published in 2005, including updates to diagnosis and management as well as new research into pharmacological and psychological treatments. These advances have been translated into clear and easy to use recommendations for first, second, and third‐ line treatments, with consideration given to levels of evidence for efficacy, clinical support based on experience, and consensus ratings of safety, tolerability, and treatment‐emergent switch risk. New to these guidelines, hierarchical rankings were created for first and second‐ line treatments recommended for acute mania, acute depression, and maintenance treatment in bipolar I disorder. Created by considering the impact of each treatment across all phases of illness, this hierarchy will further assist clinicians in making evidence‐based treatment decisions. Lithium, quetiapine, divalproex, asenapine, aripiprazole, paliperidone, risperidone, and cariprazine alone or in combination are recommended as first‐line treatments for acute mania. First‐line options for bipolar I depression include quetiapine, lurasidone plus lithium or divalproex, lithium, lamotrigine, lurasidone, or adjunctive lamotrigine. While medications that have been shown to be effective for the acute phase should generally be continued for the maintenance phase in bipolar I disorder, there are some exceptions (such as with antidepressants); and available data suggest that lithium, quetiapine, divalproex, lamotrigine, asenapine, and aripiprazole monotherapy or combination treatments should be considered first‐line for those initiating or switching treatment during the maintenance phase. In addition to addressing issues in bipolar I disorder, these guidelines also provide an overview of, and recommendations for, clinical management of bipolar II disorder, as well as advice on specific populations, such as women at various stages of the reproductive cycle, children and adolescents, and older adults. There are also discussions on the impact of specific psychiatric and medical comorbidities such as substance use, anxiety, and metabolic disorders. Finally, an overview of issues related to safety and monitoring is provided. The CANMAT and ISBD groups hope that these guidelines become a valuable tool for practitioners across the globe.

show abstract

Section: Specific Populationsmentioning

confidence: 99%

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder

et al. 2018

View full text Add to dashboard Cite

show abstract

“…We found 53 articles on OABD in the last 6 years . Of those, 50 (94%) papers examined clinical samples ranging from 10 to 315 subjects (total of 3302 subjects, mean ± standard deviation (SD) 62.3 ± 51.5 subjects/paper, median 53 subjects/paper).…”

Section: Resultsmentioning

confidence: 99%

“…All studies ( n = 53) reported age and gender. Levels of education were the next most often reported ( n = 34 studies, 64%), followed by ethnicity ( n = 23, 43%) and marital status ( n = 17, 32%) …”

Section: Resultsmentioning

confidence: 99%

“…For manic symptoms, the Young Mania Rating Scale (YMRS) was mostly widely used ( n = 29, 55%) . Several scales for depressive symptoms were used, such as the Hamilton Depression Rating Scale ( n = 21, 40%), and the Montgomery‐Asberg Depression Rating Scale (MADRS) ( n = 8, 15%), with only one study using a mood chart . Only three studies assessed for a history of psychotic symptoms (6%), and only one study reported the use of a psychotic symptom severity measure (2%) (Positive and Negative Syndrome Scale, and Scale for the Assessment of Negative Symptoms) …”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Measurement tools for assessment of older age bipolar disorder: A systematic review of the recent global literature

et al. 2017

Self Cite

View full text Add to dashboard Cite

Assessment tools used in the recent OABD literature may help to identify both a minimum and a comprehensive dataset that should be evaluated in OABD. Our review also highlights gaps where key clinical outcomes have not been routinely assessed. Biomarker and neuroimaging assessment could be further developed and standardized. Clinical data could be combined with neuroimaging, genetic, and other biomarkers in large-scale coordinated data collection to further improve our understanding of OABD phenomenology and biology, thereby contributing to research that advances care.

show abstract

“…asenapine is registered for the treatment of acute and long-term schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with BDI [8]. This was based on the results of several randomized controlled studies supporting its efficacy and good tolerability in both short-and long-term use in schizophrenic and BD patients in monotherapy [6,7,[9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26] and in BDmixed episode [27][28][29]. The recommended dose of asenapine in monotherapy is 10 mg twice a day that can be reduced to 5 mg twice a day depending on the patient's response.…”

Section: Introductionmentioning

confidence: 99%